Compare VGAS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VGAS | NEUP |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4M | 18.5M |
| IPO Year | 2021 | 2002 |
| Metric | VGAS | NEUP |
|---|---|---|
| Price | $1.00 | $3.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.8K | ★ 23.1K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,174,165.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $3.03 |
| 52 Week High | $3.36 | $5.53 |
| Indicator | VGAS | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 27.67 |
| Support Level | $0.95 | N/A |
| Resistance Level | $1.24 | $3.59 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 26.64 | 8.59 |
Verde Clean Fuels Inc is a renewable energy company specializing in the conversion of synthesis gas, or syngas, derived from diverse feedstocks, such as biomass, MSW, and mixed plastics, as well as natural gas (including synthetic natural gas) and other feedstocks, into liquid hydrocarbons that can be used as gasoline through a proprietary liquid fuels technology, the STG process.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.